Deep Longevity Will Launch Accrua Telehealth in October
The digital health platform will provide U.S. consumers with clinician-guided treatments and AI-powered biological ageing insights.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you trust digital telehealth platforms to accurately monitor your long-term biological health markers?
Deep Longevity, a subsidiary of Regent Pacific Group Limited, will launch its digital health platform Accrua across all 50 U.S. states in October 2026. The platform offers clinician-guided weight loss, peptides, and wellness services combined with the company’s AI-driven BloodAge biological ageing assessments.
Why it matters
The company is entering the U.S. consumer telehealth market to capitalize on growing demand for longevity-focused services and recurring subscription revenue. By utilizing a capital-efficient model, the platform aims to scale rapidly without the traditional overhead of clinical facility ownership.
Deep Longevity’s competitor, MEDVi, LLC, generated over US$400 million in revenue during 2025. The platform relies on a model validated by a 9.2-year study of 2,600 adults, and parent company Regent Pacific has returned approximately US$298 million to shareholders since its 1997 IPO.
The players
Deep Longevity
A subsidiary of Regent Pacific that develops AI-driven ageing-clock technology and diagnostic platforms.
Regent Pacific Group Limited
A Hong Kong-based investment holding firm that manages a portfolio of international healthcare and life sciences assets.
The details
Accrua operates as a digital intermediary, outsourcing clinical delivery to a network of independent physicians and pharmacy partners rather than owning clinical infrastructure. The platform integrates Deep Longevity’s proprietary ageing-clock technology and the SenoClock platform to provide personalized assessments alongside consumer treatments. This infrastructure-light strategy allows the firm to enter the national market while focusing investment on digital marketing and AI analysis.
Timeline
The launch of the Accrua platform is scheduled for October 2026.
Regent Pacific originally completed its initial public offering in May 1997.
Market Landscape
Accrua’s entry follows the rapid expansion of the U.S. telehealth market, where companies like MEDVi, LLC have demonstrated significant revenue potential through integrated consumer-focused models. This shift highlights a broader industry trend of moving proprietary health technology directly to the consumer via lightweight, subscription-based digital channels.
Operators in the digital health sector should monitor the performance of this capital-efficient delivery model as a potential benchmark for scaling clinical services without high fixed costs. Businesses should also evaluate whether their existing diagnostic capabilities can be integrated into recurring revenue streams to meet the rising consumer interest in longevity metrics.
The takeaway
The platform represents a strategic attempt to monetize AI-driven ageing research by tapping into the recurring revenue models common in consumer telehealth. Operators should track the platform's adoption rates as a signal for the demand level for AI-based biological age testing in the retail health market.
Further reading
For broader trends on market adoption, visit the Healthcare section.
More information
For additional corporate and platform details, visit the Deep Longevity company information portal.
Live Poll
Do you trust digital telehealth platforms to accurately monitor your long-term biological health markers?
